Innovation Pharmaceuticals Inc (IPIX)

[Whoops]

We sit at 75x the initial dose. First in human yes but what really scuttled progress was the erythema issue around cohort 2,3 and possibly lingered from there on. It wasn't really until cohort 5 that we started to see the bigger dose increases, percent-wise. Not all erythema too figuring grade2ae in stage 4 patients has to be difficult.

What interesting with Brilacidin dosing is what did or didn't happen in its phase 1 trial and what made polymed push so hard in to phase 2a especially since they had Dr. Jorgensen. Polymed collapsed mainly for reasons outside of Brilacidin and oddly Brilacidin couldn't save them. Horrible management..finances and the final blow was Delparantag. Brilacidin wasn't looking to bad coming out of phase 2a.

Just happy to be where were at now.